143 related articles for article (PubMed ID: 18445837)
1. Will we ever be ready for blood level-guided therapy?
Walko CM; McLeod HL
J Clin Oncol; 2008 May; 26(13):2078-9. PubMed ID: 18445837
[No Abstract] [Full Text] [Related]
2. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
3. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
4. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
[TBL] [Abstract][Full Text] [Related]
5. [Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
Grinev MV
Vestn Khir Im I I Grek; 2002; 161(6):100-3. PubMed ID: 12638509
[TBL] [Abstract][Full Text] [Related]
6. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols].
Boisdron-Celle M; Le Guellec C;
Therapie; 2010; 65(3):171-6. PubMed ID: 20699067
[TBL] [Abstract][Full Text] [Related]
8. Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
Fang L; Jiang Y; Yang Y; Zheng Y; Zheng J; Jiang H; Zhang S; Lin L; Zheng J; Zhang S; Zhuang X
Oncotarget; 2016 Dec; 7(49):81880-81887. PubMed ID: 27636992
[TBL] [Abstract][Full Text] [Related]
9. [Biochemical modulation by leucovorin of the antineoplastic effect of fluorofur in disseminated colorectal cancer].
Manziuk LV; Perevodchikova NI; Gorbunova VA; Luk'ianchenko AB; Abramova NA
Vopr Onkol; 1996; 42(3):33-6. PubMed ID: 8801738
[No Abstract] [Full Text] [Related]
10. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Köhne CH; Wilke H; Schöffski P; Schmoll HJ
J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?
Boisdron-Celle M
Pharmacogenomics; 2012 Oct; 13(13):1437-9. PubMed ID: 23057541
[No Abstract] [Full Text] [Related]
12. [Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
Benoit R; Grobost O; Chalmet P
Gastroenterol Clin Biol; 2000 Dec; 24(12):1241-2. PubMed ID: 11173744
[No Abstract] [Full Text] [Related]
13. [Modeling 5-FU clearance during a chronomodulated infusion].
Kwiatkowski F; Chevalier V; Chevrier R; Richard D; Cure H; Chollet P
Pathol Biol (Paris); 2003 Jun; 51(4):231-3. PubMed ID: 12852999
[TBL] [Abstract][Full Text] [Related]
14. Schedule dependency of 5-fluorouracil.
Leichman CG
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):26-32. PubMed ID: 10442355
[TBL] [Abstract][Full Text] [Related]
15. Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
Zhou X; Chang Y; Qian J; Shen C; Han J; Zhao H; Chang R
Med Sci Monit; 2021 Jul; 27():e929474. PubMed ID: 34330885
[TBL] [Abstract][Full Text] [Related]
16. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Martens-Lobenhoffer J; Fuhlroth J; Ridwelski K
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):41-4. PubMed ID: 10667836
[TBL] [Abstract][Full Text] [Related]
17. [5-Fluorouracil-induced reticular hyperpigmentation].
Sanz-Sánchez T; Córdoba S; Jiménez-Ayala B; Borbujo JM
Actas Dermosifiliogr; 2008 Sep; 99(7):573-4. PubMed ID: 18682175
[No Abstract] [Full Text] [Related]
18. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
19. Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Yang R; Zhang Y; Zhou H; Zhang P; Yang P; Tong Q; Lyu Y; Han Y
Ther Drug Monit; 2016 Feb; 38(1):79-86. PubMed ID: 26309030
[TBL] [Abstract][Full Text] [Related]
20. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin.
Aki Z; Kotiloğlu G; Ozyilkan O
Am J Gastroenterol; 2000 Apr; 95(4):1093-4. PubMed ID: 10763974
[No Abstract] [Full Text] [Related]
[Next] [New Search]
